These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33096920)

  • 41. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
    Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
    Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
    Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
    Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of alternative splicing in Drosophila by 56 RNA binding proteins.
    Brooks AN; Duff MO; May G; Yang L; Bolisetty M; Landolin J; Wan K; Sandler J; Booth BW; Celniker SE; Graveley BR; Brenner SE
    Genome Res; 2015 Nov; 25(11):1771-80. PubMed ID: 26294686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternative dystrophin gene transcripts in golden retriever muscular dystrophy.
    Schatzberg SJ; Anderson LV; Wilton SD; Kornegay JN; Mann CJ; Solomon GG; Sharp NJ
    Muscle Nerve; 1998 Aug; 21(8):991-8. PubMed ID: 9655116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
    Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles.
    Sironi M; Cagliani R; Comi GP; Pozzoli U; Bardoni A; Giorda R; Bresolin N
    FEBS Lett; 2003 Feb; 537(1-3):30-4. PubMed ID: 12606026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. When a mid-intronic variation of DMD gene creates an ESE site.
    Trabelsi M; Beugnet C; Deburgrave N; Commere V; Orhant L; Leturcq F; Chelly J
    Neuromuscul Disord; 2014 Dec; 24(12):1111-7. PubMed ID: 25193336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
    Errington SJ; Mann CJ; Fletcher S; Wilton SD
    J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abnormal splicing switch of DMD's penultimate exon compromises muscle fibre maintenance in myotonic dystrophy.
    Rau F; Lainé J; Ramanoudjame L; Ferry A; Arandel L; Delalande O; Jollet A; Dingli F; Lee KY; Peccate C; Lorain S; Kabashi E; Athanasopoulos T; Koo T; Loew D; Swanson MS; Le Rumeur E; Dickson G; Allamand V; Marie J; Furling D
    Nat Commun; 2015 May; 6():7205. PubMed ID: 26018658
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. rMAPS: RNA map analysis and plotting server for alternative exon regulation.
    Park JW; Jung S; Rouchka EC; Tseng YT; Xing Y
    Nucleic Acids Res; 2016 Jul; 44(W1):W333-8. PubMed ID: 27174931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
    Hiller M; Spitali P; Datson N; Aartsma-Rus A
    Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pseudoexons of the DMD Gene.
    Keegan NP
    J Neuromuscul Dis; 2020; 7(2):77-95. PubMed ID: 32176650
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.
    Araki E; Nakamura K; Nakao K; Kameya S; Kobayashi O; Nonaka I; Kobayashi T; Katsuki M
    Biochem Biophys Res Commun; 1997 Sep; 238(2):492-7. PubMed ID: 9299538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel cryptic exon in intron 3 of the dystrophin gene was incorporated into dystrophin mRNA with a single nucleotide deletion in exon 5.
    Suminaga R; Takeshima Y; Adachi K; Yagi M; Nakamura H; Matsuo M
    J Hum Genet; 2002; 47(4):196-201. PubMed ID: 12166656
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case of Becker muscular dystrophy resulting from the skipping of four contiguous exons (71-74) of the dystrophin gene during mRNA maturation.
    Patria SY; Alimsardjono H; Nishio H; Takeshima Y; Nakamura H; Matsuo M
    Proc Assoc Am Physicians; 1996 Jul; 108(4):308-14. PubMed ID: 8863344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.